Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 84

Cited In for PubMed (Select 11857015)

1.

Recent Enhancements to the Genetic Risk Prediction Model BRCAPRO.

Mazzola E, Blackford A, Parmigiani G, Biswas S.

Cancer Inform. 2015 May 10;14(Suppl 2):147-57. doi: 10.4137/CIN.S17292. eCollection 2015. Review.

2.

The CHEK2 1100delC allelic variant is not present in familial and sporadic breast cancer cases from Moroccan population.

Marouf C, Hajji O, Diakité B, Tazzite A, Jouhadi H, Benider A, Nadifi S.

Springerplus. 2015 Feb 1;4:38. doi: 10.1186/s40064-014-0778-5. eCollection 2015.

3.

Genetic variation in cell cycle regulatory gene AURKA and association with intrinsic breast cancer subtype.

Taylor NJ, Bensen JT, Poole C, Troester MA, Gammon MD, Luo J, Millikan RC, Olshan AF.

Mol Carcinog. 2014 Oct 18. doi: 10.1002/mc.22238. [Epub ahead of print]

PMID:
25328151
4.

The impact of reporting incidental findings from exome and whole-genome sequencing: predicted frequencies based on modeling.

Ding LE, Burnett L, Chesher D.

Genet Med. 2015 Mar;17(3):197-204. doi: 10.1038/gim.2014.94. Epub 2014 Jul 31.

5.

Breast cancer risk assessment using genetic variants and risk factors in a Singapore Chinese population.

Lee CP, Irwanto A, Salim A, Yuan JM, Liu J, Koh WP, Hartman M.

Breast Cancer Res. 2014 Jun 18;16(3):R64. doi: 10.1186/bcr3678.

6.

Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease.

Leongamornlert D, Saunders E, Dadaev T, Tymrakiewicz M, Goh C, Jugurnauth-Little S, Kozarewa I, Fenwick K, Assiotis I, Barrowdale D, Govindasami K, Guy M, Sawyer E, Wilkinson R; UKGPCS Collaborators, Antoniou AC, Eeles R, Kote-Jarai Z.

Br J Cancer. 2014 Mar 18;110(6):1663-72. doi: 10.1038/bjc.2014.30. Epub 2014 Feb 20.

7.

Estimating risks for variants of unknown significance according to their predicted pathogenicity classes with application to BRCA1.

Dowty JG, Lee E, McKean-Cowdin R, Henderson BE, Bernstein L, Ursin G, Hopper JL.

Breast Cancer Res Treat. 2014 Feb;144(1):171-7. doi: 10.1007/s10549-014-2845-6. Epub 2014 Jan 31.

8.

Comparison of mRNA splicing assay protocols across multiple laboratories: recommendations for best practice in standardized clinical testing.

Whiley PJ, de la Hoya M, Thomassen M, Becker A, Brandão R, Pedersen IS, Montagna M, Menéndez M, Quiles F, Gutiérrez-Enríquez S, De Leeneer K, Tenés A, Montalban G, Tserpelis D, Yoshimatsu T, Tirapo C, Raponi M, Caldes T, Blanco A, Santamariña M, Guidugli L, de Garibay GR, Wong M, Tancredi M, Fachal L, Ding YC, Kruse T, Lattimore V, Kwong A, Chan TL, Colombo M, De Vecchi G, Caligo M, Baralle D, Lázaro C, Couch F, Radice P, Southey MC, Neuhausen S, Houdayer C, Fackenthal J, Hansen TV, Vega A, Diez O, Blok R, Claes K, Wappenschmidt B, Walker L, Spurdle AB, Brown MA; ENIGMA consortium.

Clin Chem. 2014 Feb;60(2):341-52. doi: 10.1373/clinchem.2013.210658. Epub 2013 Nov 8.

9.

Quantitative assessment of common genetic variants on chromosome 5p12 and hormone receptor status with breast cancer risk.

Yu Y, Chen Z, Wang H, Zhang Y.

PLoS One. 2013 Aug 19;8(8):e72154. doi: 10.1371/journal.pone.0072154. eCollection 2013.

10.

Breast cancer in the young: role of the geneticist.

Woodson AH, Profato JL, Muse KI, Litton JK.

J Thorac Dis. 2013 Jun;5 Suppl 1:S19-26. doi: 10.3978/j.issn.2072-1439.2013.04.13.

11.

Analysis and prediction of pathways in HeLa cells by integrating biological levels of organization with systems-biology approaches.

Higareda-Almaraz JC, Valtierra-Gutiérrez IA, Hernandez-Ortiz M, Contreras S, Hernandez E, Encarnación-Guevara S.

PLoS One. 2013 Jun 10;8(6):e65433. doi: 10.1371/journal.pone.0065433. Print 2013. Erratum in: PLoS One. 2013;8(7). doi:10.1371/annotation/b212d5e5-7c4b-48c1-80ff-ba0d4ce87cfc. Encarnacion, Sergio [corrected to Encarnación-Guevara, Sergio].

12.

Estimating single nucleotide polymorphism associations using pedigree data: applications to breast cancer.

Barnes DR, Barrowdale D, Beesley J, Chen X; kConFab Investigators; Australian Ovarian Cancer Study Group, James PA, Hopper JL, Goldgar D, Chenevix-Trench G, Antoniou AC, Mitchell G.

Br J Cancer. 2013 Jun 25;108(12):2610-22. doi: 10.1038/bjc.2013.277. Epub 2013 Jun 11.

13.

Risk factors for second screen-detected or interval breast cancers in women with a personal history of breast cancer participating in mammography screening.

Houssami N, Abraham LA, Kerlikowske K, Buist DS, Irwig L, Lee J, Miglioretti DL.

Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):946-61. doi: 10.1158/1055-9965.EPI-12-1208-T. Epub 2013 Mar 19.

14.

Exome sequencing of germline DNA from non-BRCA1/2 familial breast cancer cases selected on the basis of aCGH tumor profiling.

Hilbers FS, Meijers CM, Laros JF, van Galen M, Hoogerbrugge N, Vasen HF, Nederlof PM, Wijnen JT, van Asperen CJ, Devilee P.

PLoS One. 2013;8(1):e55734. doi: 10.1371/journal.pone.0055734. Epub 2013 Jan 31.

15.

Recognizing BRCA gene mutation risk subsequent to breast cancer diagnosis in southwestern Ontario.

Vanstone M, Chow W, Lester L, Ainsworth P, Nisker J, Brackstone M.

Can Fam Physician. 2012 May;58(5):e258-66.

16.

The application of nonsense-mediated mRNA decay inhibition to the identification of breast cancer susceptibility genes.

Johnson JK, Waddell N; kConFab Investigators, Chenevix-Trench G.

BMC Cancer. 2012 Jun 15;12:246. doi: 10.1186/1471-2407-12-246.

17.

BRCA1/2 mutations, fertility and the grandmother effect.

da Silva J.

Proc Biol Sci. 2012 Aug 7;279(1740):2926-9. doi: 10.1098/rspb.2012.0542. Epub 2012 May 9. No abstract available.

18.

The role of BRCA1 and BRCA2 in prostate cancer.

Castro E, Eeles R.

Asian J Androl. 2012 May;14(3):409-14. doi: 10.1038/aja.2011.150. Epub 2012 Apr 23. Review.

19.

Germline BRCA1 mutations increase prostate cancer risk.

Leongamornlert D, Mahmud N, Tymrakiewicz M, Saunders E, Dadaev T, Castro E, Goh C, Govindasami K, Guy M, O'Brien L, Sawyer E, Hall A, Wilkinson R, Easton D; UKGPCS Collaborators, Goldgar D, Eeles R, Kote-Jarai Z.

Br J Cancer. 2012 May 8;106(10):1697-701. doi: 10.1038/bjc.2012.146.

20.

A genomewide screen for suppressors of Alu-mediated rearrangements reveals a role for PIF1.

Chisholm KM, Aubert SD, Freese KP, Zakian VA, King MC, Welcsh PL.

PLoS One. 2012;7(2):e30748. doi: 10.1371/journal.pone.0030748. Epub 2012 Feb 9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk